CTLA4 and metastatic colorectal cancer: In a second study, Overman et al. reported a durable clinical benefit with Nivolumab (anti-PD1) plus Ipilimumab (anti-CTLA4) in MSI-H metastatic colorectal cancer patients, with an overall survival at 12 months of 85% [493].